Compare Medtronic PLC (MDT) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs J M Smucker Co — how do they compare? Medtronic PLC trades at $87.95 (market cap $112.24B), while J M Smucker Co trades at $118.8 (market cap $12.76B). The key difference: Medtronic PLC is far larger — about 8.8× J M Smucker Co's market cap, and J M Smucker Co pays the higher dividend (3.75%). Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and J M Smucker Co for 74 Days on average.
| MDT | SJM | |
|---|---|---|
Market Cap | $112.24B | $12.76B |
Volume | 105,663,236 | 1,300,545 |
Sector | Health | Consumer Staples |
52-Week High | $105.35 | $132.34 |
52-Week Low | $73.75 | $89.53 |
Typical Hold Time | 63 Days | 74 Days |
Enterprise Value | $131.58B | $19.61B |
Dividend Yield | 3.28% | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $87.80, up 2.68% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a 13.93% net income margin and consistent dividend growth over 49 years. Revenue growth accelerated to $33.54B in 2025, and analyst consensus targets $97.80, implying 11% upside. Recent news highlights regulatory approvals for medical devices and a $4B MiniMed exchange offer.
MDT offers value with a 3.2% dividend yield and reasonable valuation (P/E 21.6), but faces headwinds from technical bearishness and rising debt. The stock's appeal hinges on execution of growth initiatives in cardiovascular and neuroscience segments, though competitive and macroeconomic risks persist.
SJM trades at $115.93, down 0.74% on the day, with a bearish technical signal and recent earnings beats. The company reported a net loss of $1.23 billion in 2025 despite revenue growth to $8.73 billion, though 2026 forecasts show a return to profitability. Analyst consensus is bullish with a $138.23 price target, and a $1.12 dividend is scheduled for September 2026.
The stock presents a mixed outlook: strong analyst support and dividend yield offer upside, but high P/E of 55.8 and recent net losses pose valuation and execution risks. Key catalysts include sustained earnings growth and margin improvement, while competitive pressures and debt levels remain concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
